Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masato Nakaguro

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
Frontiers in Oncology|February 21, 2022
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted TherapyNatsuki Saigusa, Hideaki Hirai, Yuichiro Tada, et al.
Oral Oncology|April 19, 2025
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapySatoshi Kano, Daisuke Kawakita, Yoshitaka Honma, et al.
NPJ Precision Oncology|November 5, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profilingShinji Kohsaka, Yuichiro Tada, Mizuo Ando, et al.
Head and Neck Pathology|May 13, 2021
Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 CasesJustin A Bishop, Dipti P Sajed, Ilan Weinreb, et al.
Therapeutic Advances in Medical Oncology|September 12, 2022
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinomaDaisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, et al.
The Lancet. Oncology|December 25, 2025
International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiativeRuta Gupta, Timothy Fielder, Munita Bal, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
Frontiers in Oncology|February 21, 2022
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted TherapyNatsuki Saigusa, Hideaki Hirai, Yuichiro Tada, et al.
Oral Oncology|April 19, 2025
The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapySatoshi Kano, Daisuke Kawakita, Yoshitaka Honma, et al.
NPJ Precision Oncology|November 5, 2022
Identification of novel prognostic and predictive biomarkers in salivary duct carcinoma via comprehensive molecular profilingShinji Kohsaka, Yuichiro Tada, Mizuo Ando, et al.
Head and Neck Pathology|May 13, 2021
Microsecretory Adenocarcinoma of Salivary Glands: An Expanded Series of 24 CasesJustin A Bishop, Dipti P Sajed, Ilan Weinreb, et al.
Therapeutic Advances in Medical Oncology|September 12, 2022
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinomaDaisuke Kawakita, Toshitaka Nagao, Hideaki Takahashi, et al.
The Lancet. Oncology|December 25, 2025
International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiativeRuta Gupta, Timothy Fielder, Munita Bal, et al.
Pageof 9